Arcturus Therapeutics (NASDAQ: ARCT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Valuation & Earnings

This table compares Arcturus Therapeutics and Arrowhead Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arcturus Therapeutics N/A N/A -$24.60 million ($3.99) -1.39
Arrowhead Pharmaceuticals $31.41 million 15.31 -$34.38 million ($0.47) -11.79

Arcturus Therapeutics has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

25.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 0.0% of Arcturus Therapeutics shares are held by insiders. Comparatively, 4.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Arcturus Therapeutics and Arrowhead Pharmaceuticals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics 0 3 3 0 2.50
Arrowhead Pharmaceuticals 0 3 3 0 2.50

Arcturus Therapeutics presently has a consensus price target of $3.45, suggesting a potential downside of 37.73%. Arrowhead Pharmaceuticals has a consensus price target of $4.70, suggesting a potential downside of 15.16%. Given Arrowhead Pharmaceuticals’ higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Arcturus Therapeutics.

Risk and Volatility

Arcturus Therapeutics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500.


This table compares Arcturus Therapeutics and Arrowhead Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arcturus Therapeutics N/A -36.83% -34.70%
Arrowhead Pharmaceuticals -116.17% -42.52% -32.70%


Arrowhead Pharmaceuticals beats Arcturus Therapeutics on 7 of the 11 factors compared between the two stocks.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms. The Company, through Arcturus Therapeutics Inc, its wholly owned subsidiary based in the United States, is focused on developing RNA medicines for rare, infectious, fibrotic and respiratory diseases with unmet medical needs, including cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases, as well as replicon RNA vaccines.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company’s preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company’s pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with's FREE daily email newsletter.